Keytruda marks the first perioperative anti-PD-1 treatment option for adults with PD-L1–positive resectable locally advanced ...

RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...

Approval of Zusduri was based on data from the Phase III ENVISION trial, which showed a 78% complete response at three months ...

The company focuses on specialty drugs and uses a combination of AI and human expertise to automate the process.

Mavyret marks the first and only direct-acting antiviral approved to treat both acute and chronic hepatitis C virus ...

Under terms of the deal, Bharat Biotech will lead late-stage development and scale-up of the altSonflex1-2-3 Shigella vaccine ...

In that light, the GLP-1 rebound effect is not an obstacle but an opportunity to chart a new, holistic course in obesity care ...

Marvel Comics announced a new comic book starring a superhero that lives with type 1 diabetes. The project is being developed ...

Results from a first-in-human Phase Ia/Ib trial show that LY4170156 demonstrated a notably high overall response rate in ...

Regulatory action was based on data from the Phase III IMforte trial, which showed that Zepzelca plus Tecentriq significantly ...

Delivered as a once-daily 30 mg/mL IV bolus injection over 15 seconds, Xifyrm can be used alone or alongside non-NSAID ...

The Lung Cancer Research Foundation is expanding its research advocate groups. The group is made up of lung cancer patients ...